Upper-limb RIPC performed while patients were under propofol-induced anesthesia did not show a relevant benefit among patients undergoing elective cardiac surgery. (Funded by the German Research Foundation; RIPHeart ClinicalTrials.gov number, NCT01067703.).

BackgroundRemote ischemic preconditioning (RIPC) has been suggested to protect against certain forms of organ injury after cardiac surgery. Previously, we reported the main results of RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study, a multicenter trial randomizing 1403 cardiac surgery patients receiving either RIPC or sham‐RIPC.Methods and ResultsIn this follow‐up paper, we present 1‐year follow‐up of the composite primary end point and its individual components (all‐cause mortality, myocardial infarction, stroke and acute renal failure), in a sub‐group of patients, intraoperative myocardial dysfunction assessed by transesophageal echocardiography and the incidence of postoperative neurocognitive dysfunction 5 to 7 days and 3 months after surgery. RIPC neither showed any beneficial effect on the 1‐year composite primary end point (RIPC versus sham‐RIPC 16.4% versus 16.9%) and its individual components (all‐cause mortality [3.4% versus 2.5%], myocardial infarction [7.0% versus 9.4%], stroke [2.2% versus 3.1%], acute renal failure [7.0% versus 5.7%]) nor improved intraoperative myocardial dysfunction or incidence of postoperative neurocognitive dysfunction 5 to 7 days (67 [47.5%] versus 71 [53.8%] patients) and 3 months after surgery (17 [27.9%] versus 18 [27.7%] patients), respectively.ConclusionsSimilar to our main study, RIPC had no effect on intraoperative myocardial dysfunction, neurocognitive function and long‐term outcome in cardiac surgery patients undergoing propofol anesthesia.Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01067703.

Disclosure to third parties, reproduction or publication of this documentation, or any part thereof, or the use of any information contained therein, for purposes other than provided for by this document, is prohibited without the prior and express written permission of Ventinova Medical B.V. All information is subject to change. Figures and photos may differ from the actual situation. Ventinova, Evone, Tritube, Ventrain and FCV are registered trademarks of Ventinova Medical B.V. All rights reserved. users who operate Evone. Users must be trained. Always read the Instructions for Use before use! Refer to the website https://www.ventinovamedical.com/products/evone for further information and training materials related to this product. Ventinova Medical B.V. makes no claim for use of the product other than the intended use specified herein and disclaims any liability resulting from other uses. Observe all warnings, cautions and notes. 1.2 Intended Use Evone is intended to be used for ventilation through a small-bore tube in patients where conventional ventilation by mask and/or a large-bore endotracheal tube is not preferred. Evone is intended to be used in elective procedures for less than 24 hours without the need to use inhaled anesthetic agents. 1.3 Operator Evone is intended to be used by or under direct and undivided supervision of an anesthesiologist or intensivist. For safe and effective use of the device, device specific training is required. 1.4 Patient Group All patients > 40 kg Warning: The body weight limit is based on ideal body weight. Do not use Evone with obese children with a body weight of less than 60 kg. Risk on barotrauma. 1.5 Use Environment Evone is intended to be used in operating rooms in hospitals. Warning: Correct functioning of Evone may be adversely affected by the operation of other equipment, such as high frequency electro-surgery equipment, shortwave therapy equipment, defibrillators, or MRI equipment. Risk on malfunction.